Ursodeoxycholic Acid Market Projected to witness a Single Digit CAGR during 2021 – 2027
“Ursodeoxycholic Acid Market report” provides the detailed information about the essential aspects like driving factors, major Enhancement & challenges which will define the upcoming development of the market. Moreover, the Ursodeoxycholic Acid Market report significant Incremental opportunity for investors to invest along with the thorough analysis of competitive landscape and product offerings of key players.
Ursodeoxycholic acid (UDCA) is a bile acid used to heal gallstones and to prevent and treat the advancement of cystic fibrosis-related liver diseases. It is available as a tablet or a liquid. The bile acid pool is altered by UDCA, which reduces the fraction of hydrophobic bile acids while increases the amount of innocuous hydrophilic bile acids. UDCA can slow the advancement of gastroesophaegal varices and cirrhosis. Furthermore, it can help individuals with primary biliary cirrhosis live longer.
The global ursodeoxycholic acid market had a valuation of US$ 457.3 million in 2017 and is anticipated to grow at a CAGR of 10.1 percent from 2018 to 2026.
Ursodeoxycholic acid is being utilized more often to treat persistent cholestatic liver disease. The rising incidence of cystic fibrosis and gall stones is expected to propel the global ursodeoxycholic acid market forward over the forecast period. According to the Cystic Fibrosis Foundation, about 30,000 individuals in the U.S. have cystic fibrosis in 2015. Furthermore, around 1,000 new instances of cystic fibrosis are detected each year in the country. Gallstones impact 10-15 percent of the U.S. population each year or about 25 million individuals, according to a 2017 report by the American Gastroenterological Association.
In comparison to males, women are more prone to acquire gallstones. Gallstones in women are caused by high estrogen levels during pregnancy, birth control pills, or hormone replacement treatment. Gallstones are also more common in elderly people and individuals who have a family history of gallstones. Surgery is the most common therapy for symptomatic gallstones, however, ursodeoxycholic acid can dissolve smaller stones comprised mostly of cholesterol.
The global ursodeoxycholic acid market is anticipated to expand due to an increase in research studies on the use of ursodeoxycholic acid (UDCA) in different disease indications. According to a research published in August 2018 by the University of Sheffield, UDCA improves mitochondrial dysfunction, which is known to be a cause of both sporadic and familial Alzheimer’s disease.
Scientists concluded that UDCA might protect dopamine cells produced in culture against apoptosis, or programmed cell death, by controlling a particular cell preservation pathway, according to a 2018 paper published by the Cure Parkinson’s Trust in the U.K.
According to a research released in 2016 by the National Center for Biotechnology Information (NCBI), UDCA can be used as a new strategy for treating Parkinson’s disease by inhibiting apoptosis and inflammation.
With its anti-inflammatory effects, UDCA can also decrease rotenone-induced nuclear factor-B expression and tumor necrosis factor alpha levels.
However, disadvantages such as limited effectiveness (about 40 percent), delayed action, and the potential of stone recurrence are projected to stifle the global ursodeoxycholic acid market expansion.
According to a study published by National Center for Biotechnology Information (NCBI) in 2016, UDCA can be introduced as a novel approach for management of Parkinson’s disease through anti-apoptotic and anti-inflammatory mechanisms.
Purchase this Report at Discount Of US $2000 Flat OFF – https://www.coherentmarketinsights.com/promo/buynow/2199
Ursodeoxycholic Acid Market – Competitive Landscape
Key players functioning in the global prosthetic liners market consists of Dipharma Francis Srl, ERREGIERRE S.p.A., Grindeks, Industria Chimica Emiliana, Mitsubishi Tanabe Pharma Corporation, Zhongshan Belling Biotechnology Co., Glenmark Pharmaceutical Limited, Abil Chempharma Private Limited, Biotavia Labs Pvt Ltd, Daewoong Bio Inc., PharmaZell GmbH, and Suzhou Tianlu Bio-pharmaceutical Co., Ltd.
Main points in Ursodeoxycholic Acid Market Report Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Global Ursodeoxycholic Acid Market Size Analysis from 2021 to 2027
11.6 COVID-19 Outbreak: Ursodeoxycholic Acid Industry Impact
Chapter 2 Global Ursodeoxycholic Acid Competition by Types, Applications, and Top Regions and Countries
2.1 Global Ursodeoxycholic Acid (Volume and Value) by Type
2.3 Global Ursodeoxycholic Acid (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Ursodeoxycholic Acid Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Ursodeoxycholic Acid Market Analysis
Chapter 6 East Asia Ursodeoxycholic Acid Market Analysis
Chapter 7 Europe Ursodeoxycholic Acid Market Analysis
Chapter 8 South Asia Ursodeoxycholic Acid Market Analysis
Chapter 9 Southeast Asia Ursodeoxycholic Acid Market Analysis
Chapter 10 Middle East Ursodeoxycholic Acid Market Analysis
Chapter 11 Africa Ursodeoxycholic Acid Market Analysis
Chapter 12 Oceania Ursodeoxycholic Acid Market Analysis
Chapter 13 South America Ursodeoxycholic Acid Market Analysis
Chapter 14 Company Profiles and Key Figures in Ursodeoxycholic Acid Business
Chapter 15 Global Ursodeoxycholic Acid Market Forecast (2021-2027)
Chapter 16 Conclusions
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
- CDN Newswire